文献速递膀胱癌与上尿路尿路上皮癌

输尿管支架是否增加膀胱肿瘤患者异时性上尿路尿路上皮癌风险:系统评价与荟萃分析

Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis.
PubMed 文献 · J Urol · 2020-12-07

该系统评价与荟萃分析纳入5项研究共3309例患者,比较输尿管支架、肾造瘘或无引流对上尿路尿路上皮癌异时发生风险的影响。结果显示,放置输尿管支架者发生异时性上尿路尿路上皮癌的风险高于无支架者和无上尿路引流者,支架与肾造瘘之间无差异,所有指标证据等级均为低。

要点

  • 膀胱肿瘤患者放置输尿管支架与异时性上尿路尿路上皮癌风险升高相关。
  • 肿瘤累及输尿管口切除术后应尽量避免以支架作为预防措施。
  • 合并肾积水时,肾造瘘或支架均可选择,两者风险无差异。

核心结论

  • 输尿管支架可能增加膀胱肿瘤患者异时性上尿路尿路上皮癌风险,肿瘤累及输尿管口切除术后应尽量避免以支架作为预防措施。
  • 合并肾积水时,肾造瘘或支架引流对异时性上尿路尿路上皮癌风险无差异,可按个体情况选择。

研究设计与样本

  • 系统评价与荟萃分析,比较输尿管支架与肾造瘘或无引流对异时性上尿路尿路上皮癌风险的影响。
  • 278例放置输尿管支架,131例接受肾造瘘治疗。

主要发现

  • 输尿管支架组20例(7.2%)发生异时性上尿路尿路上皮癌,肾造瘘组3例(2.3%)发生。
  • 与无支架相比,输尿管支架与异时性上尿路尿路上皮癌风险升高相关(OR:3.49,95%CI:1.43-8.48,I2=52%)。
  • 与无上尿路引流相比,输尿管支架风险亦升高(OR:3.37,95%CI:1.49-7.63,I2=45%)。
  • 支架与肾造瘘之间无差异(OR:3.07,95%CI:0.41-22.98,I2=54%);合并肾积水患者中同样未见差异。
  • 所有指标的证据等级均评为低。

关键数值与推荐

  • 异时性上尿路尿路上皮癌发生率:支架组7.2%(20/278),肾造瘘组2.3%(3/131)。
  • 支架 vs 无支架:OR 3.49(95%CI 1.43-8.48,I2=52%)。
  • 支架 vs 无上尿路引流:OR 3.37(95%CI 1.49-7.63,I2=45%)。
  • 支架 vs 肾造瘘:OR 3.07(95%CI 0.41-22.98,I2=54%)。

临床怎么用

  • 膀胱肿瘤累及输尿管口行经尿道切除时,如可能应避免放置输尿管支架作为预防措施。
  • 存在肾积水需上尿路引流时,肾造瘘或支架均可,依据个体情况选择。

局限性

  • 纳入研究仅5项,总体证据等级评为低。
  • 支架与肾造瘘比较的置信区间宽(0.41-22.98),结果不确定性大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ureteral stenting in patients with bladder cancer may become necessary in order to protect the ureteral orifice during transurethral resection of the tumor or for relief of upper urinary tract obstruction. However, it is believed to increase metachronous upper tract urothelial carcinoma risk. MATERIALS AND METHODS: We performed a systematic review and meta-analysis of studies comparing ureteral stenting versus nephrostomy or no drainage with regard to the risk of metachronous upper tract urothelial carcinoma. Records were identified through database searches and sources of grey literature up to October 2020 (PROSPERO: CRD42020178298). RESULTS: Five studies (3,309 individuals) were included. Overall, 278 ureteral stents were placed and 20 (7.2%) patients developed metachronous upper tract urothelial carcinoma, while 131 patients were treated with nephrostomy and 3 (2.3%) cases of metachronous upper tract urothelial carcinoma occurred. Patients treated with ureteral stents had a higher likelihood of metachronous upper tract urothelial carcinoma compared to no stents (OR: 3.49, 95% CI: 1.43-8.48, I2=52%) and no upper urinary tract drainage (OR: 3.37, 95% CI: 1.49-7.63, I2=45%). No difference with regard to metachronous upper tract urothelial carcinoma was observed between stent and nephrostomy (OR: 3.07, 95% CI: 0.41-22.98, I2=54%). For the same outcomes, no difference was noted for patients with hydronephrosis. The level of evidence for all measures was evaluated as low. CONCLUSIONS: Stenting as a preventive measure after resection of tumors involving the orifice should be avoided, when possible, as it increases the risk of metachronous upper tract urothelial carcinoma. In cases of hydronephrosis, drainage with either nephrostomy or stent is recommended depending on individual patient cases as both interventions do not differ regarding metachronous upper tract urothelial carcinoma risk.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Sountoulides P, Pyrgidis N, Brookman-May S, et al. Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis. J Urol. 2020. PMID: 33284711. doi:10.1097/JU.0000000000001548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。